Literature DB >> 7461266

A metabolite of sulphinpyrazone that is largely responsible for the effect of the drug on the platelet prostaglandin pathway.

G F Pay, R B Wallis, D Zelaschi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7461266     DOI： 10.1042/bst0080727

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN： 0300-5127            Impact factor:   5.407


× No keyword cloud information.
  3 in total

Review 1.  Prodrugs.

Authors:  D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

2.  Effects of ischaemic heart disease, Crohn's disease and antimicrobial therapy on the pharmacokinetics of sulphinpyrazone.

Authors:  H A Strong; R Angus; J Oates; J Sembi; P Howarth; A G Renwick; C F George
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

3.  Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.

Authors:  I D Bradbrook; V A John; P J Morrison; H J Rogers; R G Spector
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.